CA-ENLIGHTED
16.7.2020 12:02:06 CEST | Business Wire | Press release
Enlighted , the leading building IoT platform provider, expands its award-winning IoT technology with workplace digital contact tracing to help employees return safely to manufacturing facilities, pharmaceutical labs, offices and more. Safe provides digital contact history for employees who self-report testing positive for COVID-19 to help reduce the spread of infection, keep healthy employees safe and productive, and eliminate the tedious, expensive and error-prone manual contact tracing process for employers.
The solution prioritizes data privacy without the need for storing personal information. Employees are assigned alphanumeric ID badges while entering the workplace. When an employee self-reports their badge ID and a positive test result, administrators query the Safe application, identify other IDs this badge came in contact with and share the anonymous IDs. Employees carrying those badge IDs can self-identify their exposure.
The Enlighted solution provides employers with location and proximity data to identify who an infected employee came in contact with inside the workplace, for how long and what areas they visited. The data is used to inform employees who might be at risk of infection and also drives sanitization efforts in areas the infected employee utilized. The application’s dashboard provides information on contacts in the building to assist management in developing safer workplace strategies. Additionally, Safe identifies how many close contacts are happening in a time period and location to proactively manage risk.
Enlighted is in a unique position to provide proven safer workplace solutions for COVID-19 and beyond with its IoT technology already installed in 320 million square feet of buildings globally. Existing customers can simply add the Safe app to their IoT platform. New customers can install the Enlighted IoT system through sensors in LED lighting or through the new USB-powered surface sensor , which can be easily applied under desks or in conference rooms.
“The important role of IoT technology in buildings has been further magnified by the COVID-19 pandemic,” said Stefan Schwab, CEO of Enlighted, a Siemens company. “The Enlighted sensory system can now provide digital contact tracing. It also lays the foundation for future-proofed buildings ready to help us understand with real-time data the changing nature of our at-work experiences and meet challenges beyond COVID-19.”
Enlighted offers a suite of data-driven safer workplace solutions , assisting planners in preparing and executing physical distancing processes, enhanced sanitization and monitoring, occupancy limits and now contact tracing. The IoT platform also integrates through APIs with third-party systems to provide touchless entry, smart desk hoteling, conference room booking and more.
The Safe application is available immediately for new and existing Enlighted customers. Visit www.enlightedinc.com/contact-sales to talk with a sales representative or request a demonstration, or visit http://www.enlightedinc.com to learn about Enlighted’s full suite of workplace safety solutions.
ABOUT ENLIGHTED
Designed to change everything, Enlighted provides the world’s most advanced Building IoT Platform for leading commercial and healthcare organizations around the globe, with more than 320 million square feet of building space deployed to date. Founded in 2009 and headquartered in Silicon Valley, Enlighted was acquired in 2018 and is a wholly-owned subsidiary of Siemens Industry, Inc. as part of Siemens Smart Infrastructure. For more information about Enlighted, visit enlightedinc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
